The pharmaceutical CDMO sector is worth paying close attention to.



1: WuXi AppTec, annual non-recurring net profit increased by 32.56%, Q1 2026 increased by 83.56%. A-shares hit the daily limit, Hong Kong stocks rose 15%.

2: Kelun Pharmaceutical, annual non-recurring net profit increased by 22.01%, Q1 2026 decreased by 10.88%. A-shares hit the daily limit, Hong Kong stocks nearly hit the limit.

3: Kanglong Chemical, annual non-recurring net profit increased by 38.85%, Q1 2026 not yet released.

4: Tigermed, annual non-recurring net profit decreased by 58.47%, Q1 2026 not yet released.

5: Zhaoyan New Drug, annual non-recurring net profit increased by 1221.3%, Q1 2026 not yet released.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments